The effects of antidepressants in Parkinson's disease: A meta-analysis

International Journal of Neuroscience

Volumn 118, Issue 5, 2008, Pages 667-682

  Frisina, Pasquale G ^a,b   Tenenbaum, Harriet R ^c   Borod, Joan C ^b,d   Foldi, Nancy S ^d,e  

^a Jewish Home and Hospital   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c KINGSTON UNIVERSITY   (United Kingdom)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Depression; Meta analysis; Parkinson's disease; Treatment

Indexed keywords

IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGITATION; ALLERGIC REACTION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DEPRESSION; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; MEMORY DISORDER; META ANALYSIS; MIGRAINE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT MONITORING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SIDE EFFECT; SLEEP DISORDER; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; URINE RETENTION; VOMITING;

ANTIDEPRESSIVE AGENTS; DRUG EVALUATION; FEMALE; HUMANS; MALE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 43049121419     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.1080/00207450701239418     Document Type: Article

References (54)

1. *Allain, H., Cougnard, J., & Neukirch, H. C. (1991). Selegiline in de novo parkinsonian patients: The French selegiline multicenter trial (FSMT). Acta Neurologica Scandinavica, 136, 73-78.
2. *Anderson, J., Aabro, E., Gulmann, N., Hjelmsted, A., & Pedersen, H. E. (1980). Anti-depressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-dopa. Acta Neurologica Scandinavica, 62, 210-219.
3. Caley, C. F., & Friedman, J. H. (1992). Does fluoxetine exacerbate Parkinson's disease? Journal of Clinical Psychiatry, 53, 278-282.
4. Ceravolo, R., Nuti, A., Piccinni, A., Dell'Agnell, G., Bellini, G., Gambaccini, G., Dell'Osso, L., Murri, L., & Onnuccelli, U. (2000). Paroxetine in Parkinson's disease: Effects on motor and depressive symptoms. Neurology, 55, 1216-1218.
5. Cohen, J. (1988). Statistical power analysis for the behavioral sciences. Hillsdale, NJ: Erlbaum.
6. Cummings, J. L. (1992). Depression and Parkinson's disease: A review. American Journal of Psychiatry, 149, 443-454.
7. *Dalrymple-Alford, J. C., Jamieson, C. F., & Donaldson, I. M. G. (1995). Effects of selegiline on cognition in early Parkinson's disease. Clinical Neuropharmacology, 18, 348-359.
8. Fiske, S. T., Schacter, D. L., & Zahn-Waxler, C. (2001). Meta-analysis: Recent developments in quantitative methods for literature reviews. Annual Review of Psychology, 52, 59-82.
9. Glass, G. V., McGaw, B., & Smith, M. L. (1981). Meta-analysis in social research. Beverly Hills, CA: Sage Publications.
10. *Golbe, L. I., & Duvoisin, R. C. (1987). Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease. Journal of Neural Transmission, 25, 123-129.
11. Hauser, R. A., & Zesiewicz, T. A. (1997). Sertraline for the treatment of depression in Parkinson's disease. Movement Disorders, 12, 756-759.
12. Hedges, L. V., & Olkin, I. (1985). Statistical methods for meta-analysis. Orlando, FL: Academic Press.
13. *Hietanen, M. H. (1991). Selegiline and cognitive function in Parkinson's disease. Acta Neurologica Scandinavica, 84, 407-410.
14. Hornykiewicz, O. (1982). Imbalance of brain monoamines and clinical disorders. Progress in Brain Research, 55, 419-421.
15. *Hubble, J. P., Koller, W. C., &Waters, C. (1993). Effects of selegiline dosing on motor fluctuations in Parkinson's disease. Clinical Neuropharmacology, 16, 83-87.
16. *Indaco, A., & Carrieri, P. D. (1988). Amitriptyline in the treatment of headache in patients with Parkinson's disease. Neurology, 38, 1720-1722.
17. Ives, N. J., Stowe, R. L., Marro, J., Counsell, C., Macleod, A., Clarke, C. E., Gray, R., &Wheatley, K. (2004). Monoamine oxidase type B inhibitors in early Parkinson's disease: Meta-analysis of 17 randomized trials involving 3525 patients. Retrieved September 10, 2004, from the Pubmed database. URL=www.ncbi.nlm.gov/pubmed.
18. Jimenez-Jimenez, F. J., Tejeiro, J., Martinez-Junquera, G., Cabrera-Valdivia, F., Alarcon, J., & Garcia-Albea, E. (1994). Parkinsonism exacerbated by paroxetine. Neurology, 44, 240-246.
19. Johnson, B. T. (1990). DSTAT: Software for the meta-analytic review of research literatures. Hillsdale, NJ: Erlbaum.
20. Klaassen, T., Verhey, F. R. J., Sneijders, G. H. J., Rozendaal, N., de Vet, H. C. W., & van Praag, H. M. (1995). Treatment of depression in Parkinson's disease: A metaanalysis. Journal of Neuropsychiatry and Clinical Neurosciences, 7, 281-286.
21. *Laitinen, L. (1969). Desipramine in treatment of Parkinson's disease. Acta Neurologica Scandinavica, 45, 109-113.
22. *Larsen, J. P., Boas, J., & Erdal, J. E. (1999). Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish study group. European Journal of Neurology, 6, 539-547.
23. Leentjens, A. F. G., Verhey, F. R. J., Luijckx, G. J., & Troost, J. (2000). The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Movement Disorders, 6, 1221-1224.
24. *Leentjens, A. F. G., Vreeling, F. W., Luijckx, G. J., & Verhey, F. R. J. (2003). SSRIs in the treatment of depression in Parkinson's disease. International Journal of Geriatric Psychiatry, 18, 552-554.
25. *Lees, A. J., Kohout, L. J., Shaw, K. M., Stern, G. M., Elsworth, J. D., Sandler, M., & Youdam, M. B. H. (1977). Deprenyl in Parkinson's disease. The Lancet, 2, 791-795.
26. MacGillivray, S., Arroll, B., Hatcher, S., Ogston, S., Reid, I., Sullivan, F., Williams, B., & Cromble, L. (2003). Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: Systematic review and meta-analysis. British Medical Journal, 326, 1014-1017.
27. Mann, J., & Gershon, S. (1980). L-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous depression. Life Science, 2, 877-882.
28. Mann, J. J., Aarons, S. F., Wilner, P. J., Keilp, J. G., Sweeney, J. A., Pearlstein, T., Frances, A. J., Kocsis, J. H., & Brown, R. P. (1989). A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor. Archives of General Psychiatry, 46, 45-50.
29. Mendlewicz, J., & Youdim, B. H. (1983). L-deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double blind evaluation. British Journal of Psychiatry, 142, 508-511.
30. Montastruc, J. L., Fabre, N., Blin, O., Senard, J. M., Rascol, O., & Roscol, A. (1995). Does fluoxetine aggravate Parkinson's disease? A pilot prospective study. Movement Disorders, 10, 355-357.
31. Morrison, C., Borod, J., Brin, M., Halbig, T., & Olanow, C. W. (2004). Effects of levodopa on cognitive functioning in moderate-to-severe Parkinson's disease (MTSPD). Journal of Neural Transmission, 111, 1333-1341.
32. *Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1991). Selegiline as a primary treatment of Parkinson's disease. Acta Neurologica Scandinavica, 84, 70-72.
33. *Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1992). Selegiline as initial treatment in de novo parkinsonian patients. Neurology, 42, 339-343.
34. *Myllyla, V. V., Sotaniemi, K. A., Vuorinen, J. A., & Heinonen, E. H. (1993). Selegiline in de novo parkinsonian patients: The Finnish study. Movement Disorders, 8, S41-S44.
35. *Myllyla, V. V., Heinonen, E. H., Vuorinen, J. A., Kilkku, O. I., & Sotaniemi, K. A. (1995). Early selegiline therapy reduces levodopa dose requirment in Parkinson's disease. Acta Neurologica Scandinavica, 91, 177-182.
36. *Myllyla, V. V., Sotaniemi, K. A., Hakulinen, P., Maki-Ikola, O., & Heinonen, E. H. (1997). Selegiline as the primary treatment of Parkinson's disease - a long-term double-blind study. Acta Neurologica Scandinavica, 95, 211-218.
37. Orwin, R. G. (1983). A fail safe N for effect size in meta-analysis. Journal for Educational Statistics, 8, 157-159.
38. *Parkinson Study Group. (1989). Effects of deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine, 321, 1364-1371.
39. *Parkinson Study Group. (1993). Effects of tocopherol and Deprenyl on the progression of disability in early Parkinson's disease. New England Journal of Medicine, 328, 176-183.
40. Poewe, W., & Seppi, K. (2001). Treatment options for depression and psychosis in Parkinson's disease. Journal of Neurology, 248, III/12-III/21.
41. *Przuntek, H., & Kuhn, W. (1987). The effect of r-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. Journal of Neural Transmission, 25, 97-104.
42. *Przuntek, H., Conrad, B., Dichgans, J., Kraus, P. H., Krauseneck, P., Pergande, G., Rinne, U., Schimrigk, K., Schnitker, J., & Vogel, H. P. (1999). SELDO: A 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. European Journal of Neurology, 6, 141-150.
43. Rampello, L., Chiechio, S., Raffaele, R., Vecchio, I., & Nicoletti, F. (2002). The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clinical Neuropharmacology, 25, 21-24.
44. Rosenthal, R. (1984). Meta-analytic procedures for social research. Beverly Hills, CA: Sage.
45. *Shoulson, I., Oakes, D., Fahn, S., Lang, A., Langston, W. J., LeWitt, P., Olanow, W., Penney, J. B., Tanner, C., Kieburtz, K., Rudolph, A., & the Parkinson Study Group. (2002). Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: A randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Annals of Neurology, 51, 604-612.
46. Slaughter, J. R., Slaughter, K. A., Nichols, D., Holmes, S. E., & Martens, M. P. (2001). Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neuroscience, 13, 187-196.
47. Strang, R. R. (1965). Imipramine in treatment of Parkinsonism: A double-blind placebo study. British Medical Journal, 2, 33-34.
48. *Takahashi, M., Yuasa, R., Imai, T., Tachibana, H., Yorifuji, S., Nakamura, Y., & Ogawa, N. (1994). Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: A double-blind trial. Internal Medicine, 33, 517-524.
49. Tesei, S., Antonini, A., Canesi, M., Zecchinelli, A., Mariani, C. B., & Pezzoli, G. (2000). Tolerability of paroxetine in Parkinson's disease: A prospective study. Movement Disorders, 15, 986-989.
50. *Waters, C. H., Sethi, K. D., Hauser, R. A., Molho, E., Bertoni, J. M., & the Zydis Selegiline Study Group. (2004). Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3-month, randomized, placebo-controlled study. Movement Disorders, 19, 426-432.
51. Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005). Antidepressant studies in Parkinson's disease: A review and meta-analysis. Movement Disorders, 20, 1161-1169.
52. *Wermuth, L., Sorensen, P. S., Timm, S., Christensen, B., Utzon, N. P., Boas, J., Dupont, E., Hansen, E., Magnussen, I., Mikkelsen, B., Worm-Petersen, J., Lauritzen, L., Bayer, L., & Bech, P. (1998). Depression in idiopathic Parkinson's disease treated with citalopram. Nord Journal of Psychiatry, 52, 163-169.
53. Wilson, K., & Mottram, P. (2004). A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: A meta-analysis. International Journal of Geriatric Psychiatry, 19, 754-762.
54. Zgaljardic, D., Borod, J., Foldi, N., & Mattis, P. (2003). A review of the cognitive and behavioral sequelae of Parkinson's disease: Relationship to fronto-striatal circuitry. Cognitive Behavioral Neurology, 16, 193-210.